Improved treatment option for patients with previously treated IDH-1 mutated cholangiocarcinoma (bile duct cancer) (Ivosidenib)

Impact: Health and wellbeing

Narrative

I was involved in the development of the protocol of the first randomised study to show benefit from the targeted treatment Ivosidenib (known as Tibsovo) in patients with cholangiocarcinoma (bile duct cancer) harbouring a mutation in the IDH-1 gene. In August 2021, FDA approved Ivosidenib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with IDH1 mutation.
Impact date2019
Category of impactHealth and wellbeing
Impact levelAdoption

Research Beacons, Institutes and Platforms

  • Cancer
  • Manchester Cancer Research Centre

Related content